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ABSTRACT
The main methods for producing genetically engin-
eered cells use viral vectors for which safety issues
and manufacturing costs remain a concern. In
addition, selection of desired cells typically relies
on the use of cytotoxic drugs with long culture
times. Here, we introduce an efficient non-viral
approach combining the Sleeping Beauty (SB)
Transposon System with selective proliferation of
engineered cells by chemically induced dimerization
(CID) of growth factor receptors. Minicircles
carrying a SB transposon cassette containing a
reporter transgene and a gene for the F36VFGFR1
fusion protein were delivered to the hematopoietic
cell line Ba/F3. Stably-transduced Ba/F3 cell popu-
lations with >98% purity were obtained within
1week using this positive selection strategy. Copy
number analysis by quantitative PCR (qPCR)
revealed that CID-selected cells contain on
average higher copy numbers of transgenes than
flow cytometry-selected cells, demonstrating se-
lective advantage for cells with multiple transposon
insertions. A diverse population of cells is present
both before and after culture in CID media, although
site-specific qPCR of transposon junctions show
that population diversity is significantly reduced
after selection due to preferential expansion of
clones with multiple integration events. This
non-viral, positive selection approach is an attract-
ive alternative for producing engineered cells.
INTRODUCTION
Genetically engineered cells are essential elements of
biotechnologies ranging from recombinant protein pro-
duction to cell therapy (1,2). However, several limitations
and inefﬁciencies still remain in generating engineered
cells. The preparation of stably transformed cell lines
with high protein production efﬁciency is a current limi-
tation in the manufacture of recombinant proteins (3). As
a result, hundreds of clonal cell lines are typically screened
to identify high production cell lines. For cell therapy ap-
plications, integrating viral vectors such as retrovirus are
commonly used to stably transduce cells, and this
approach raises safety concerns due to the possibility of
insertional mutagenesis mediated by the non-random in-
tegration pattern of most integrating viruses (4). Clinical
grade viral vectors are also costly to manufacture. The
desired cells then need to be selected and/or ampliﬁed to
necessary quantities and purities (5,6). Technologies that
improve and simplify the manufacturing process for cell
therapies are critical in facilitating clinical translation and
adoption of these approaches.
The Sleeping Beauty (SB) transposon system is an at-
tractive, non-viral alternative to viral delivery systems (7).
This DNA transposon system was revived by molecular
reconstruction of inactive sequences from ﬁsh by Ivics and
coworkers (8). Since this discovery, the SB transposon
system has become one of the most widely used transpos-
ition systems for non-viral gene therapy and has been
approved for human clinical trials in a T-cell therapy
application (9). Although insertional mutagenesis caused
by transposition is still a possibility, SB transposition has
safety advantages over most of the commonly-used
integrating vector systems [retrovirus, lentivirus and
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ence for integrating in transcriptional units and their
upstream regulatory sequences (10,11). The SB
transposase enzyme, that can be given in trans as DNA
or RNA, inserts the transposon expression cassette into
mammalian cells through a ‘cut and paste’ mechanism.
The transposase binds to terminal inverted repeats (IR)
that contain SB-binding elements (DR), excises the
sequence ﬂanked by the repeats, and integrates the trans-
poson into thymine–adenine (TA) sites in the genome (8).
However, both non-viral transfection and transposon in-
tegration efﬁciencies are low in primary cell types and
therefore prolonged culture time is typically required to
propagate the desired cells.
In this work, we present a non-viral approach for
expedited and enriched generation of engineered cells
by combining SB integration technology with chemically
responsive ampliﬁcation mechanisms. Speciﬁc signaling
pathways can be chemically controlled using fusion
proteins of small molecule-responsive dimerization
domains with signaling domains that are activated upon
dimerization (12,13). A F36VFGFR-1 fusion protein con-
structed by Whitney et al. (14) contains the modiﬁed
FK506 protein (F36V) that binds to the chemical inducer
of dimerization (CID) AP20187 fused to the cytoplasmic
domain of the ﬁbroblast growth factor receptor-1
(FGFR-1). When dimerized, FGFR-1 initiates several sig-
naling pathways that include cell proliferation (15).
CID-dependent signaling through the F36VFGFR-1 con-
structprovidesbothspeciﬁcityandcontrol.WhileFGFR-1
is activated through different ﬁbroblast growth factors and
requires heparin, F36VFGFR-1 is activated speciﬁcally by
the presence of AP20187 (15). Removal of AP20187 also
terminates activation of F36VFGFR-1 (16,17).
A SB transposon cassette containing two genes,
encoding enhanced green ﬂuorescent protein (EGFP)
reporter and F36VFGFR-1, was constructed. We
hypothesized that cells with successful transposition
could be selectively ampliﬁed through CID-stimulated
proliferation as an approach to overcome the limitations
of poor non-viral transfection and low integration fre-
quency. We report that using this non-viral gene transfer
and ampliﬁcation approach, nearly-pure populations
(>98% containing integrated transposon cassettes) of a
murine hematopoietic cell line (Ba/F3) could be obtained
within 7 days of CID selection. Integration analysis sug-
gested that multiple insertion sites were being preferen-
tially selected through this process.
MATERIALS AND METHODS
Plasmids
The pT3/eGIF plasmid that carries the T3 SB transposon
cassette containing an EF1a promoter, EGFP gene, IRES
and F36VFGFR1 gene was constructed using standard
molecular biology cloning techniques from pT3-MSCV-
U3-GFP (generously provided by Richard A. Morgan,
National Cancer Institute) and pMGIF36Vfgf (generously
provided by Charles Murry, University of Washington)
(14,18). To create pMCT3/eGIF, the plasmid for
producing minicircles, the NdeI/SbfI fragment of
pT3/eGIF containing only the transposon cassette was
blunt-ended and cloned into EcoRV site of
pMC.BESPX (generously provided by Mark A. Kay,
Stanford University) (19,20). Minicircles were produced
from this plasmid and puriﬁed according to System
Biosciences user manual for minicircle DNA vector tech-
nology. The CMV(CAT)T7-SB100X plasmid containing
the hyperactive variant of Sleeping Beauty transposase
SB100X was a generous gift from Zsuzsanna Izsvak
(Max Delbruck Center for Molecular Medicine, Berlin,
Germany). All plasmids were ampliﬁed under endotoxin-
free conditions using Qiagen Endofree Plasmid Kit.
Ba/F3 culture and transfection
Ba/F3 cells were cultured in RPMI with 10% FBS and 1%
antibiotic/antimicotic supplemented with mrIL-3 5ng/ml
(BD Bioscience). The optimized nucleofection protocol for
Ba/F3 cells using Nucleofector (Lonza) was followed
(program X-001, Nucleofector Kit V). Two million cells
were used per nucleofection with varying amounts of
plasmid DNA. Cells were grown in IL-3 containing
media for a week after nucleofection to achieve stable
transfection. For CID selection, cells were cultured in
RPMI with 10% FBS and 1% antibiotic/antimicotic
with 100nM AP20187 (ARIAD Pharmaceuticals, Inc).
Flow cytometric analysis
For ﬂow cytometry analysis, live cells were selected based
on propidium iodide exclusion by adding propidium
iodide in the ﬂow cytometry buffer to 4mg/ml. To stain
for the HA tag on F36VFGFR1, cells were ﬁxed on ice in
2% paraformaldehyde, resuspended in ice-cold methanol,
washed with permeabilization staining buffer (PBS,
0.5% BSA, 0.1% saponin), resuspended in PBS with
anti-HA-PE antibodies (Miltenyi Biotec Inc) at a 1:10
dilution and incubated for 30min in the dark at room
temperature. Cells were then washed and resuspended in
PBS with 0.3% BSA for ﬂow cytometry. Flow cytometric
analysis was carried out on Becton Dickinson FACScan
using analysis using FlowJo software. Appropriate
negative controls (untransfected Ba/F3 cells with and
without propidium iodide staining) were used for compen-
sation and gating. A Becton Dickinson FACSAria II was
used for cell sorting. All ﬂow cytometry work was con-
ducted at the UW Immunology Flow Cytometry Facility.
Growth analysis
Ba/F3 cells were washed with PBS and diluted to the con-
centration of 300000 cells/ml and grown in RPMI with
10% FBS and 1% antibiotic/antimicotic with, or without
factors (IL-3 or AP20187). Concentration of live cells was
measured by trypan blue exclusion in hemocytometer
every 2 days.
Determination of transposon copy number
Genomic DNA was extracted using Puregene Kit A ac-
cording to manufacturer’s instructions (Qiagen) and
qPCR was performed in Applied Biosystems 7300
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Green Master Mix (Applied Biosystems). Primers used for
qPCR were designed using Primer3 software (http://
simgene.com/Primer3): EGFP forward primer: 50-ACGT
AAACGGCCACAAGTTC, EGFP reverse primer: 50-AA
GTCGTGCTGCTTCATGTG, albumin forward primer:
50-CTCAGGTGTCAACCCCAACT, albumin reverse
primer: 50-CCACACAAGGCAGTCTCTGA. EGFP
primers are speciﬁc for the EGFP gene in the transposon,
and ALBm primers are speciﬁc for the Albumin gene, that
is represented at a single copy in mouse haploid genome.
Standard curves were generated using genomic DNA of a
BaF3 clone with a single insertion of transposon. This
clone was obtained by diluting the culture to single cell
suspension and growing colonies in 96-well plate. Several
colonies were then screened for single insertions by using
qPCR to determine the absolute copy number of GFP
gene. An amount of 10ng of genomic DNA was used in
qPCR for determination of transposon copy number.
Copy number was calculated using CT method (21). To
determine the representation of identiﬁed integration sites
in cell populations, primer pairs were designed for individ-
ual transposon junctions (Supplementary Table S2). PCR
products were used to generate standard curves, and copy
number determined using an absolute quantitation
method (22).
Integration site analysis
Integration site analysis was done by Linear Ampliﬁcation
Mediated Polymerase Chain Reaction (LAM-PCR) (23),
as modiﬁed by Harkey et al. (24) and adapted here for SB
vectors. Brieﬂy, a single-stranded copy of the vector-host
junction was generated by linear extension from a
biotinylated vector primer. This single-stranded junction
fragment was trapped and isolated on Streptavidin-coated
magnetic beads, and converted to double-stranded DNA
by random primed polymerization. Three aliquots of
junction DNA were digested with three separate
four-base restriction endonucleases (Tsp509I, RsaI or
HaeIII) chosen to cut at the nearest host site. An anchor
primer was ligated to the newly exposed ends and the
junction region was ampliﬁed by nested PCR. The com-
plexity of the population of integration sites was initially
observed by the complexity of PCR products seen by
4–20% polyacrylamide gel electrophoresis. Individual
insertion sites were identiﬁed by cloning fragments
eluted from the gel and sequencing individual clones.
Unique primers for SB were as follows: biotinylated ex-
tension primer: 50-biotin-TGTGGTGTAGTTGAAAAA
CGAG, nested primer #1: TTTTAATGACTCCAACTT
AAGTG, and nested primer #2: TATGTAAACTTCCGA
CTTCAAC. Additional primers were as described previ-
ously (24).
RESULTS
pT3/eGIF plasmid and minicircle construction
The pT3/eGIF plasmid that carries the hyperactive trans-
poson (T3) cassette containing both the EGFP reporter
gene and the F36VFGFR-1 gene expressed under the
EF1a (elongation factor-1a) promoter through an
internal ribosome entry sequence (IRES) was constructed
(Figure 1). The hyperactive transposon, developed by
Yant et al., contains a duplication of the left IR/DR struc-
ture in the transposon along with additional ﬂanking
TA dinucleotides and has been shown to be three times
more active than the original transposon sequences (25).
The analogous plasmid (pT3/mGIF, 8.3kb) with the
murine stem cell virus (MSCV) promoter was also
Figure 1. The SB transposon system combined with chemical-induced dimerization (CID). (A) Constructs used in this study. pT3/eGIF plasmid
carries the SB transposon containing of the EF1a promoter, eGFP gene, Internal Ribosome Entry Site (IRES) and a fusion gene of synthetic
dimerization domain F36V and a Fibroblast Growth Factor Receptor 1 (FGFR1), positioned between Inverted Terminal Repeats (ITRs, black
arrows); mcT3/eGIF is the minicircle derived from pT3/eGIF and SB100X plasmid contains the hyperactive SB transposase SB100X under the CMV
promoter. (B) CID (AP20187) selection for cells with integrated transposon. Transfected cells expressing the F36VFGFR1 protein undergo selective
proliferation through CID-induced cell signaling. After selection, a nearly homogenous population of stably transduced cells is obtained.
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because they have both been shown to drive strong expres-
sion across different types of cells, including stem cells
(26,27) The EF1a promoter drove more robust transgene
expression (4–5 times) than the MSCV promoter in Ba/F3
cells (data not shown) so the EF1a promoter construct
was used for all remaining studies.
In our initial studies, we noted that cell viability after
nucleofection was inversely related to the amount of DNA
present during nucleofection. To optimize the delivery
of our transgene, we also prepared minicircles of the
T3/eGIF transposon (mcT3/eGIF) that lack the bacterial
plasmid backbone (19,20). Transposon cassettes were
cloned into a minicircle production plasmid and mini-
circles were generated by recombination of ﬂanking attB
and attP sites followed by degradation of the plasmid
DNA backbone.
Transfection studies were performed in the IL-3 de-
pendent, FGFR-1 responsive pro-B cell line Ba/F3 using
nucleofection for gene delivery. The efﬁciency of
nucleofection was 4 times higher for minicircles carrying
transposon, than the pT3/eGIF plasmid, when equal
amount of the DNA was used (Figure 2A). The mean
GFP ﬂuorescence of the transfected population is similar
for both minicircle- and plasmid-transfected cells,
indicating that expression efﬁciency is similar between
the two constructs. No difference in cell viability after
nucleofection was observed as well (data not shown).
Next, the transposon integration efﬁciency was tested by
codelivery of mcT3/eGIF with the SB100X transposase
plasmid by ﬂow cytometry analysis for EGFP-positive
cells 24h and 7 days post-nucleofection to assess for efﬁ-
ciency of transient and stable expression, respectively. By
Day 7 post-nucleofection, delivered transposon in the
absence of transposase was eliminated, resulting in 0.1%
EGFP
+ cells. In contrast,  5% of live cells (or 25% of
transientlytransfectedpopulation)carriedintegratedtrans-
posons due to codelivery of transposase (Figure 2B).
Increasing the transposon to transposase plasmids ratio
from 1:2 to 1:1 (by mass) did not signiﬁcantly affect trans-
position efﬁciency.
Transformed Ba/F3 cells are selectively ampliﬁed by CID
selection and show CID-dependent proliferation
Pools of Ba/F3 cells with a starting integrated transposon
frequency of  5% were cultured in the presence of
100nM AP20187 in IL3-free conditions to allow for
CID selection. Ba/F3 cells are normally IL-3 dependent.
The population of transformed cells was monitored by
ﬂow cytometry at 2, 4 and 7 days post-selection. The per-
centage of EGFP
+ cells in the live cell population
(negative for propidium iodide staining) increased
steadily, reaching >98% with 7 days of CID selection
(Figure 3A). Transformed cells maintained in IL-3 kept
a stable population of 5.6±1.8% of EGFP
+ cells
(Figure 3A). The growth kinetics of transformed Ba/F3
cells grown in IL3 and CID was also determined
(Figure 3B). Control (untransfected) Ba/F3 and trans-
fected Ba/F3 cells showed similar growth curves when
cultured in IL-3 containing media. Transfected Ba/F3
cells decreased in population 2 days after transitioning
to CID-containing, IL-3-deﬁcient media due to death of
untransformed cells. However, cell numbers began to
increase at 4 days post-selection and continued to
expand with CID-induced proliferation. The doubling
time of transformed Ba/F3 cells under CID expansion
was similar as control cells growing in IL-3 media
(doubling time of 19–23h, data not shown). As
expected, control Ba/F3 cells were unable to survive in
the absence of IL-3.
Expression of EGFP and F36VFGFR1 was monitored
by EGFP ﬂuorescence and an antibody against a
Figure 2. Transient and stable transfection of Ba/F3 cells using SB transposon system. (A) Comparison of transient transfection efﬁciency by
nucleofection delivery of plasmid and minicircle bearing T3/eGIF transposon. Ba/F3 cells were nucleofected with 5mg of either plasmid pT3/
eGIF or minicircle mcT3/eGIF. Flow cytometry was performed 24h after nucleofection. (B) Integration of T3/eGIF transposon. Ba/F3 cells
were nucleofected with varying DNA amounts of transposon minicircle mcT3/eGIF and transposase plasmid pSB100x. Flow cytometry was per-
formed 24h (gray bars) and 7days (striped bars) after nucleofection to assess transient and stable transfection efﬁciency, respectively. Bars represent
SD of three independent transfections. Averages of mean ﬂuorescence intensity of GFP
+/PI
  populations are indicated above the graphs in RFU.
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and post-selection (representative plots shown in Figure
4B). The dual positive cell population increased from
6.4±2.1% pre-selection to 96.6±2.0% post-selection.
Another 1.4% of cells were EGFP positive but did not
stain positive for F36VFGFR1. The mean ﬂuorescence
of the EGFP
+ population also increased from 565±25
relative ﬂuorescence units (RFU) to 1065±91 RFU
post-selection. Cell viability after selection was assessed
by propidium iodide (PI) exclusion staining (Figure 4A).
Before selection, cells that have recovered from
nucleofection are healthy (<5% PI
+). After CID selection,
two major populations of cells exist: live, EGFP
+ cells
(33%) and dead cells (65%). The dead cells are the
untransfected cells (EGFP
 ) that do not survive after
IL-3 withdrawal.
Because SB integration is random, it is theoretically
possible that transformed cells could proliferate independ-
ently of IL-3 or CID due to an insertional mutagenesis
event. To exclude this low probability event, a cell
survival study after IL-3 and CID withdrawal was con-
ducted with three Ba/F3 populations: untransfected Ba/F3
(control WT), stably transfected Ba/F3 selected by ﬂow
cytometry, and stably transfected Ba/F3 selected by CID
culture for 2 weeks (Figure 5). The ﬁrst two populations
were cultured in IL-3 containing media prior to factor
withdrawal. As reported previously, removal of IL-3
from control Ba/F3 cells results in loss of cell viability
that begins within 24h after factor withdrawal. (28)
Removal of IL-3 from stably transfected cells also
resulted in cell death with similar kinetics as control
cells. CID withdrawal from CID-selected cells reversed
proliferation and resulted in cell death. The population
decline rate for this group was similar to the control,
except for the 4 days offset.
Growth of stably transduced Ba/F3 cells in the presence
of CID leads to selection of a subpopulation with multiple
transposon insertions
The average copy number of integrated transposons
before and at various durations of CID selection (2, 6
and 10 weeks) was determined by real-time quantitative
polymerase chain reaction (qPCR) with primers speciﬁc
for the Egfp gene (transposon detection) and Album
(albumin, a single copy gene) (Figure 6). A puriﬁed popu-
lation of stably transduced Ba/F3 cells growing in IL-3
conditions was selected by ﬂow cytometry 3 weeks
post-transfection. The average transposon copy number
in this stably transfected cell pool was 1.3±0.1 per
haploid genome. This number was increased to 2.9±0.3
after 2 weeks of CID selection and did not increase further
with longer selection times. These data suggest that cells
with multiple insertion sites have an advantage when
cultured with dimerizer.
It is possible that cells with F36VFGFR1 integration at
certain sites show preferential growth characteristics due
Figure 3. Proliferation of transfected Ba/F3 cells cultured in IL-3 or CID-containing media. (A) Flow cytometry analysis of stably transfected
populations of BaF3 cells with T3/eGIF transposon, grown in the presence of CID (AP20187) or IL-3 at different time points. (B) Growth curve of
untransfected (WT) or SD transfected (T3/eGIF) Ba/F3 cells cultured in either IL-3 or CID (AP20187) containing media. An arrow indicates time
(Day 0) when CID selection commenced. Bars represent SDs of three independent cultures.
PAGE 5 OF 10 Nucleic Acids Research,2012, Vol.40, No. 11 e85Figure 4. Flow cytometry scattergrams of Ba/F3 cells stably transfected with T3/eGIF transposon, pre- and post-selection with CID. (A) GFP versus
Propidium Iodine (PI). (B) GFP versus HA-PE (F36VFGFR1-HA expression). Pre-selection, cells were cultured in IL-3 media. Post-selection, cells
were cultured in media containing 100nM CID (AP20187) for 7 days.
Figure 5. Cell survival after withdrawal of IL-3 or CID. Three differ-
ent Ba/F3 cell populations were investigated for survival: wild-type
BaF3 (WT) after IL-3 withdrawal, Ba/F3 cells stably transduced with
T3/eGIF transposon, selected by ﬂow cytometry, after IL-3 withdrawal
and stably transduced Ba/F3cells with T3/eGIF transposon selected by
CID, after CID withdrawal. An arrow indicates the time of factors
withdrawal (Day 0). Bars represent SDs of three independent cultures.
Figure 6. Transposon copy number per mouse haploid genome.
Genomic DNA was isolated from population of Ba/F3 cells stably
transfected with T3/eGIF transposon, before and after CID selection
at different time points. The average transposon copy number was
determined by quantitative PCR. Bars represent SDs of three independ-
ent experiments. *P<0.01 compared to IL-3-treated cells by t-test
analysis.
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itional effects and as a result may be over-represented in
CID-ampliﬁed populations. CID withdrawal experiments
showed that Ba/F3 cell growth remained dependent on
either IL-3 or CID (Figure 5). To assess the possibility
of preferential site integration, integration sites in Ba/F3
cells before and after CID ampliﬁcation were determined
by linear ampliﬁcation-mediated PCR (LAM–PCR)
Multiarm LAM–PCR has been shown to improve detec-
tion capacity compared to single-arm LAM–PCR; thus,
three-arm LAM–PCR with restriction enzymes HaeIII,
Tsp509I and RsaI was conducted (24). Each of the three
independently-derived populations of Ba/F3 cells trans-
fected with the SB100X and mcT3/eGIF constructs were
cultured in IL-3 for 2 weeks and then split into two
groups. One group was cultured in IL-3 conditions
(‘IL-3’ group) and the second group (‘CID’ group) was
grown with AP20187 for 2 weeks before LAM–PCR
analysis. The electrophoretic banding proﬁles generated
by the three-arm LAM–PCR analyses are shown in
Supplementary Figure S1. The non-selected samples
show complex but distinct patterns, indicative of
multiple integration events. The three CID-selected
samples also show complex patterns but the distribution
of bands changes after CID-selection and remain unique
for each sample. We also took one sample and separated it
into three groups for CID selection. The distributions of
bands from these three CID-selected samples were similar,
showing that the initial population does determine the in-
tegration patterns after CID selection (Supplementary
Figure S1, lanes B1, B2, B3).
Finally, at least 10 integration sites from independent
CID-selected populations were determined by sequencing
(Supplementary Table S1). In random samplings of inser-
tion site sequences, 80–100% of the reactions yielded
unique sites for each cell population tested. These results
suggest that a heterogeneous population of clones remains
after 2 weeks of CID selection. To ascertain relative rep-
resentation of speciﬁc clones after CID selection, the copy
number of speciﬁc integration sites was determined by
absolute quantitation of qPCR results. Three randomly
selected individual transposon junctions were detected in
CID-selected populations from which they were identiﬁed
at all time points (2, 6 and 10 weeks of selection) at
anywhere between 0.7% and 25% of cells. These junctions
were not detected in either the parent-unselected popula-
tion nor the other CID selected pools. These results
indicate that there is a substantial variation in the repre-
sentation of individual clones, and that there is no detect-
able overlap of integration sites between individual
experiments.
DISCUSSION
In this work, we present a positive-selection approach for
generating engineered mammalian cells. By combining
SB transposon technology and CID technology, desired
cells are generated by non-viral transfection followed
by selective proliferation of desired cells responsive to
a small molecule trigger. This method provides safety,
cost, and time advantages over the commonly used proto-
cols of viral transduction followed by drug selection.
In comparison with integrating viruses, such as human
immunodeﬁciency virus type 1 (HIV-1) and murine
leukemia virus (MLV) (29,30), SB shows lower integration
preference for intragenic regions (10,25,31). For clinical
cell therapy applications, GMP-grade virus must also be
produced.
Positive selection of cells addresses the main disadvan-
tages of drug selection, which is the predominant
approach for isolating engineered cells (6,32). Cytocidal
culture conditions reduce the growth rate of cells,
exacerbating the already limiting parameter of prolonged
culture times required for cell production (33). In contrast,
CID-induced proliferation by FGFR activation has been
shown to increase the proliferation rate in several cell
types compared to control cells (34,35). Also, the
method of selecting stably transduced cells has been
shown to affect the heterogeneity of the resulting popula-
tion, with drug selection yielding cells with mosaic expres-
sion patterns due to gene silencing (36). We show in this
work that CID-dependent cell ampliﬁcation selects for
high expression of transgene. Because growth is dependent
on continuous CID selection over several days, a bias
toward engineered cells with more temporally homoge-
neous expression patterns is also expected.
CID technology has been used to affect cell signaling
via several protein partners including T cell receptor
domains, erythropoietin receptor (EpoR) and mpl
receptor. For this work, the F36VFGFR1 construct
was chosen because it has been used to trigger expan-
sion of both short-term repopulating hematopoietic stem
cells (HSCs) and skeletal myoblasts, and is therefore
relevant for cell therapy applications (14,16,17). IL-3
dependent, proB Ba/F3 cells were selected as a model
hematopoietic cell line because the constitutively active
BCR–FGFR1 fusion protein responsible for cases of
chronic myeloid leukemia has been shown to render
this cell line IL-3 independent (37). In addition, Blau
et al. (13) showed that CID-based signaling through
the EpoR can also remove IL-3 dependency in these
cells. Transfection of Ba/F3 cells has been used exten-
sively as an approach to identify and/or validate poten-
tial oncogenes (38–40).
Lipid, cationic polymer and electroporation delivery
approaches were tested to optimize transfection of
Ba/F3 cells. Of these, nucleofection was found to give
relatively high transient transfection of plasmids. The
latest generation of hyperactive SB transposon and
transposase were both used. The T3 transposon contains
extra ﬂanking TA dinucleotides, important for transposon
excision, and a duplication of the left IR/DR sequence,
important for transposase binding and multimerization
(25,41,42). SB100X is a hyperactive transposase developed
through a PCR-based DNA-shufﬂing strategy followed by
screening of activity in mammalian cells (43). SB100X was
shown to be 100-fold more potent in transposition than
the original protein.
Minicircle vectors were used to carry the transposon
cassette. The cell survival after nucleofection has been
reported to increase with decreasing amount of delivered
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The amount and sequence of DNA between the trans-
poson ends has also been shown to affect transposition;
shorter DNA segments result in increased transposition
efﬁciency (42). This observation was attributed to the
transposase complex binding to one end of the transposon
and then searching bidirectionally for the second end.
Minicircle delivery of transposon cassettes is therefore
an attractive alternative to plasmid delivery.
Transfection efﬁciency by nucleofection of Ba/F3 cells is
four times higher when minicircles are used (Figure 2A).
In addition to improved delivery and transposition
efﬁciencies, minicricles may offer reduced inﬂammation
from CpG responses (20).
CID selection for 1 week allowed us to produce a nearly
pure (98%) population of cells carrying transposon due to
preferential survival and proliferation of cells expressing
F36VFGFR1 when grown in CID media (Figure 3A).
Dual expression of both transgenes, EGFP and
F36VFGFR1, was conﬁrmed in >96% of surviving cells
by ﬂow cytometry (Figure 4). The growth rate of cells after
CID selection in the presence of AP20187 is similar to that
of control Ba/F3 cells grown in Il-3 conditions, with a
doubling time of 19–23h (data not shown). While
FGFR1 dimerization initiates a complicated signaling
cascade, there are common proteins involved with IL-3
activation. The MAP kinase signaling pathway is
activated by CID-induced FGFR1 dimerization and also
by IL-3 stimulation of Ba/F3 cells (14,34,45,46). In
addition, inhibition of FGFR activity has been shown to
lead to downregulation of cyclin D proteins, a MAP
kinase-regulated protein and IL-3 withdrawal from IL-3
cells also reduces cyclin D levels in Ba/F3 (47,48).
CID-dependent proliferation of engineered cells
was conﬁrmed by cell death upon withdrawal of CID
(Figure 5). The time lag observed between CID with-
drawal and cell death may be attributed to remaining
intracellular CID and the positive feedback downstream
of FGFR1 signaling. Indeed, Xian et al. note that
phosphorylated MAP kinase ERK1 (pERK1) levels are
reduced after dimerizer withdrawal from mammary epi-
thelial cells but remain elevated compared to controls
(49). The same effect was also observed after CID with-
drawal from F36VFGFR1 transduced myoblasts (14).
Finally, it is interesting to note that withdrawal of
dimerizer from Ba/F3 cells induced to proliferate due to
EpoR1 activation results in a 5-day time lag before decline
in cell numbers is observed (13).
Integration site analysis revealed the presence of a
complex population of clones bearing stable SB integrants
whether the cells were grown in IL-3 or selected with CID
treatment (Supplementary Figure S1). The altered integra-
tion site patterns caused by CID suggest selection of a
subpopulation of clones. This supports our conclusion
from qPCR that clones with higher copy numbers are
selected (Figure 6). Selection of clones with higher copy
numbers may be advantageous for biotechnology applica-
tions due to the potential of increased protein production
efﬁciency. For cell therapy applications, higher number of
integration events increases the possibility of insertional
mutagenesis. Copy number analysis of identiﬁed
individual integration sites reveal that representation
of clones is uneven, with some being represented in 25%
of the CID-selected population. Therefore, the diversity of
clones is substantially reduced after CID selection. The
pattern of CID selected sites is determined by the
original pool of transposition events, since speciﬁc trans-
poson junctions were detected only in the population in
which they were identiﬁed.
In summary, we demonstrate here that a nearly pure
population of stably transduced cells can be generated
by non-viral delivery of desired transgenes through a com-
bination of SB transposon-mediated integration and se-
lective ampliﬁcation using chemically induced dimerizer.
We anticipate that this approach may be used to produce
engineered cells for biotechnology and clinical cell therapy
applications.Dimerizer-induced growth provides cost and
reproducibility advantages to natural ligand stimulation in
ex vivo cell culture, and also provides a means to control
engineered cell behavior in vivo (17). While the FGFR1-
signaling pathway was used in this work to stimulate pro-
liferation, the choice of CID-responsive fusion protein can
be tailored for the application of interest. Future work will
include application of this described approach to primary
HSCs. F36VFGFR1-induced proliferation of murine
HSCs has been shown to expand short term HSCs that
eventually differentiate to granulocytes and monocytes
(17), and may be a viable approach for generating engin-
eered monocytes or monocyte-derived cells.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables S1 and S2, Supplementary
Figure S1.
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